Skip to content

Opioid-Sparing Protocol Comparing With Opioid-based Protocol After Bilateral Total Knee Arthroplasty

Opioid-Sparing Protocol Using for Postoperative Pain Management Comparing With Opioid-based Patient Control Analgesia After Simultaneous Bilateral Total Knee Arthroplasty: a Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04314505
Enrollment
56
Registered
2020-03-19
Start date
2020-03-20
Completion date
2020-08-20
Last updated
2020-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Replacement, Opioid Use, Postoperative Pain

Keywords

Bilateral Total Knee Arthroplasty, Opioid Use, Opioid Sparing, Postoperative pain

Brief summary

The concern for the opioid use in the total knee arthroplasty continues to rise in recent decades. Historically, the total knee arthroplasty consumed high doses opioids in the postoperative periods. Compared to the Opioid-Based patient controlled analgesia(PCA), the opioid-sparing protocol may have benefits to decrease the concerns of the opioid use and opioid-related complication and provides the equivalent efficacy for pain control. The purpose of this trial in to provide a novel opioid-sparing protocol (OSP) to evaluate the efficacy for pain control and reducing the immediate postoperative opioid consumption.

Interventions

After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. In the opioid-sparing group, a dose of Parecoxib sodium 40 mg was administrated through intravenous route before the incision. After the surgery, Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.

DRUGOpioid-Based Patient Controlled Analgesia

After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg\*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.

Sponsors

Taipei Veterans General Hospital, Taiwan
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* patient with bilateral advanced knee osteoarthritis undergoing simultaneous bilateral total knee arthroplasty surgery * willing to participate in this study and randomly allocated to either opioid-sparing protocol or PCA protocol.

Exclusion criteria

* patient who refused to participate or with contraindication or hypersensitivity to any of the study drugs * chronic pain disorder (exceeding 50 mg oral morphine equivalence per day at time of recruitment) * substance abuse (e.g. alcoholism) * severe renal impairment.

Design outcomes

Primary

MeasureTime frameDescription
Pain scores using numerical rating scale (VAS, 0 to 10) at restPost-operative 6 hours after surgeryPost-operative 6 hours
Pain scores using numerical rating scale (VAS, 0 to 10) at motionPost-operative 24 hours after surgeryPost-operative 24 hours

Secondary

MeasureTime frameDescription
drug-related (opioid) adverse events0-72 hours after surgerynausea/vomiting, dizziness, urinary retention, pruritus, dry mouth, constipation, dyspepsia, GI bleeding, pitting edema over lower extremities, cardiovascular event, respiratory depression, delirium or coma
maximum angle of continuous passive motion (CPM) as tolerated (Degrees)0-72 hours after surgeryrecorded at post-operative 24 hours, 48 hours and 72 hours
Length of hospital stay (LOS) (Days)After surgery until discharge (about 3-5 days after surgery)Time from admission to discharge
Satisfaction scale (0-100 points)postoperative 2 weeks after surgerysatisfaction with regard to the efficacy and safety of the pain management protocol.
Cumulative morphine consumption(mg)0-72 hours after surgeryrecorded at post-operative 24 hours, 48 hours and 72 hours

Countries

Taiwan

Contacts

Primary ContactHsuan-Hsiao Ma, M.D.
tyc20192@gmail.com02-28717557

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026